PALI

Palisade Bio, Inc.
CAPPED RATING

Palisade Bio, Inc. (PALI) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
C
Factor Score 2.2 / 5.0
Growth
F
Factor Score 0.5 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 1.2
EV / EBITDA -1.8
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M -47.9%
Price Return 12M -45.1%
Catalyst Signal 0.00
Market Cap $201.0M
TTM Revenue $500.0K
Price / Sales 402.0
ROE -75.6%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C (2.2) F (0.5) C- (2.0) D+ (1.7) C+ (2.6) D+ (1.8)
2026-11-07 C (2.3) F (0.6) C (2.2) D+ (1.7) C+ (2.7) C- (1.9)
2026-10-31 C (2.3) F (0.5) C- (2.1) D+ (1.5) C+ (2.7) D+ (1.8)
2026-10-24 C- (2.1) F (0.6) C- (2.1) D+ (1.7) C+ (2.6) D+ (1.8)
2026-10-17 C- (2.1) F (0.5) C- (2.1) C- (1.9) C+ (2.6) D+ (1.8)
Page 1 of 4